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Purpose: This study aimed to evaluate the efficacy of simultaneous computed tomography (CT) and quantitative
CT (QCT) in patients with osteoporotic hip fracture (OHF) by analyzing the osteoporosis detection rate and
physician prescription rate in comparison with those of conventional dual-energy X-ray absorptiometry (DXA).
Materials and Methods: This study included consecutive patients older than 65 years who underwent internal
fixation or hip arthroplasty for OHF between February and May 2015. The patients were assigned to either the
QCT (47 patients) or DXA group (51 patients). The patients in the QCT group underwent QCT with hip CT,
whereas those in the DXA group underwent DXA after surgery, before discharge, or in the outpatient clinic. In
both groups, the patients received osteoporosis medication according to their QCT or DXA results. The
osteoporosis evaluation rate and prescription rate were determined at discharge, postoperative (PO) day 2, PO
day 6, and PO week 12 during an outpatient clinic visit.
Results: The osteoporosis evaluation rate at PO week 12 was 70.6% (36 of 51 patients) in the DXA group and
100% in the QCT group (P<0.01). The prescription rates of osteoporosis medication at discharge were 70.2%
and 29.4% (P<0.001) and the cumulative prescription rates at PO week 12 were 87.2% and 60.8% (P=0.003) in
the QCT and DXA groups, respectively.
Conclusion: Simultaneous CT and QCT significantly increased the evaluation and prescription rates in patients
with OHF and may enable appropriate and consistent prescription of osteoporosis medication, which may
eventually lead to patients’ medication compliance.
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INTRODUCTION
Osteoporosis is a systemic disease of the bone and a leading
cause of fractures that can result in deterioration of bone
strength1). Osteoporotic hip fracture (OHF) is associated
with high mortality and morbidity, and is particularly fatal
in the elderly2-4). A large number of patients with OHF are
unable to ambulate independently, and OHF can be associated
with simultaneous fractures in other parts of the body5-8).
Consequently, effective management and adequate medication
treatment of OHF are important for lowering the risk of
associated fractures, mortality, and morbidity2-4). However,
patients with osteoporotic fractures are less likely to be
evaluated and managed for osteoporosis by physicians who
are responsible for treating symptomatic fractures9,10). A
systematic review indicated that bone mineral density (BMD)
scans are performed for fewer than 15% of osteoporotic
fracture patients11). Another report indicated that osteoporosis
treatment is initiated for 1% to 22% of patients with hip
fracture19,12,13). The reason for these low rates is not clear, but
physicians, especially orthopedic surgeons, may still be more
focused on fracture operation rather than postoperative
(PO) treatment. Given the high lifetime risk of osteoporotic
fracture14,15), evaluation and treatment rates seem to be lower
than expected.
Dual-energy X-ray absorptiometry (DXA) and quantitative
computed tomography (QCT) are the most common
diagnostic modalities for osteoporosis16). QCT can be used
to measure BMD in three dimensions and allows to measure
volumetric trabecular bone density accurately without
superimposition of cortical bone or other tissues. The
advantage of DXA is its ability to detect small changes in
bone mineral content with low-dose radiation exposure17-19),
whereas the advantage of QCT is that data on the mineral
contents of the cortical and trabecular bones are displayed
separately, with the localization of the fracture to be studied.
Likewise, QCT and DXA are useful in the diagnosis of
BMD with different mechanisms. The superiority of either
modality over the other may differ depending on accessibility,
patient’s pain and gait ability, and other factors. Patients
with hip fractures usually need CT scans for evaluation of
the fracture pattern and for operative planning. We assumed
that if osteoporosis evaluation can be performed along with
routine CT for fracture evaluation, this would be better and
more effective for osteoporosis treatment after surgery.
Accordingly, our study aimed to evaluate the efficacy
of simultaneous CT and QCT in patients with OHF by
analyzing the prescription rate of osteoporosis medication
in comparison with that of conventional DXA. We
hypothesized that simultaneous CT and QCT would increase
the prescription rate of osteoporosis medication, as QCT
can be performed concurrently with CT without additional
movement and tests.
MATERIALS AND METHODS
This prospective study was approved by the Institutional
Review Board at Yonsei University College of Medicine (no.
1-2015-0034), and all of the patients provided informed
consent.
1. Patients and Settings
This study included consecutive patients older than 65
years who underwent internal fixation or hip arthroplasty
for OHF (peritrochanteric or femur neck fracture) between
February and May 2015 (Fig. 1). Patients with a medical
history of cancerous conditions, rheumatoid disease, or
severe comorbidities such as liver or kidney disease were
excluded. Patients who had been taking osteoporosis
medications were also excluded. We included 108 patients,
of whom 6 were lost at follow-up, 3 died from cardiopulmonary
disease, and 1 was transferred to another department
(Rehabilitation Medicine) in order to receive treatment for
osteoporosis; these 10 patients were excluded from the
analyses. Finally, 98 patients were included in the study and
were assigned to either the QCT or DXA group. The QCT
group (47 patients) underwent QCT just after undergoing
CT upon admission to the emergency department. The
DXA group (51 patients) underwent DXA after surgery,
before discharge, or in the outpatient clinic if evaluation
was not performed during the admission period. The patients
were not randomly assigned. Simultaneous QCT and CT
scans were only possible from 6:00 p.m. to 11:00 p.m. on
weekdays and from 9:00 a.m. to 6:00 p.m. on weekends
in our hospital. Patients who could undergo QCT and
CT simultaneously before surgery were assigned to the
QCT group. Those who could not undergo QCT and CT
simultaneously or who had previously undergone CT in
other facilities were assigned to the DXA group.
In the QCT group, all the patients were scanned by using
a Somatom Sensation 16 CT scanner (Siemens, Erlangen,
Germany) just after hip CT scan. QCT was performed by
using the QCT Pro calibration phantom and software
system with the CTXA Hip analysis module (Mindways
Software, Inc., Austin, TX, USA). In the DXA group, all
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the patients were scanned by using a Discovery DXA system
(Hologic, Inc., Bedford, MA, USA). Closed reduction and
internal fixation with the Zimmer Natural Nail System
(Zimmer, Warsaw, IN, USA) or Proximal Femoral Nail
(DePuy Synthes, Zuchwil, Switzerland) was performed for
peritrochanteric fractures, bipolar hemiarthroplasty was
performed with a Summit stem and Self-centering System
(DePuy Synthes, Warsaw, IN, USA) for displaced femur
neck fractures, and multiple screw fixation was performed
for non-displaced femur neck fractures. No statistically
significant differences in fracture type or operation methods
were observed between the two groups (P=0.647). The
patients were encouraged to engage in tolerable ambulation
exercise using a walker or crutches or range of motion
exercise.
No significant difference in the mean length of hospital
stay (4.2±2.4 vs. 4.0±1.9, P=0.457) was observed between
the two groups. Most of the patients were transferred to
other facilities for rehabilitation after discharge (43 patients
[91.5%] in the QCT group vs. 45 patients [88.2%] in the
DXA group, P=0.426). Outpatient clinic visits after discharge
were at PO week 2 for stitch out, and at PO weeks 6 and
12. In both groups, we prescribed osteoporosis medication
(bisphosphonate or selective estrogen receptor modulators)
according to QCT or DXA results. For the QCT group,
because we had already obtained the QCT results for all
of the patients before surgery, we prescribed osteoporosis
medication before discharge. If osteoporosis medication
was not prescribed upon discharge, we prescribed it at
every visit to the outpatient clinic. For the DXA group, our
routine protocol was to prescribe DXA at PO day 2, but
if DXA was not prescribed at that time, it was prescribed
at PO week 2 (the first visit to the outpatient clinic) and
PO week 6 just before visiting the outpatient clinic. If
DXA was not prescribed at PO weeks 2 and 6, it was
prescribed at PO month 3. We prescribed osteoporosis
medications according to DXA results.
2. Statistical Analysis
The osteoporosis evaluation rate and prescription rate
were determined at discharge, and at PO day 2, PO day
6, and PO week 12 during outpatient clinic visits. The
results were compared between the groups by using the
Student t-test for continuous data and the chi-square test
for categorical data. Statistical analysis was performed by
using the IBM SPSS Statistics version 20.0 software for
Windows (IBM Corp., Armonk, NY, USA). P-values less
than 0.05 were considered statistically significant.
Fig. 1. Flowchart of this study.
Fx: fracture, QCT: quantitative computed tomography, DXA: dual-energy X-ray absorptiometry, BMD: bone mineral density,
PO: postoperative.
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RESULTS
No difference in age was observed between the two
groups (Table 1). The mean trabecular BMD of L1-L4
as measured by using QCT was 72.95±4.78 mg/cm3, and
the mean BMD of L1-L4 as measured by using DXA was
–4.33±0.89. The mean trabecular BMD of the hip as
measured by QCT was 73.35±4.9 mg/cm3, and the mean
BMD of the hip as measured by DXA was –4.31±0.99
(Table 1). Osteoporosis evaluation rates and physician
prescription rates after surgery are shown in Table 2, and
Fig. 2 and 3. The osteoporosis evaluation rate by QCT
was 100% (Table 2 and Fig. 2) because all of the patients
assigned to the QCT group underwent QCT along with hip
Table 1. Demographic Characteristics of the Patients in the QCT and DXA Groups
Characteristic
Group
P-value
QCT (n=47) DXA (n=51)
Age (yr) 078.89±10.35 78.10±9.63 0.694
Sex 0.829
Male 12 (25.5)0 14 (27.5)0
Female 35 (74.5)0 37 (72.5)0
Height (cm) 158.27±7.940 158.44±7.580 0.915
Weight (kg) 055.88±10.71 057.69±10.72 0.403
Body mass index (kg/m2) 22.24±3.59 22.90±3.46 0.358
Fracture 0.747
Peritrochanteric fracture 19 (40.43) 19 (37.25)
Femur neck fracture 28 (59.57) 32 (62.75)
Surgery 0.945
Fixation 23 (44.69) 22 (43.13)
Bipolar hemiarthroplasty 26 (55.32) 29 (56.86)
Mean BMD (mg/cm3)
Spine 72.95±4.78 –4.33±0.89
Femur 73.35±4.99 –4.31±0.99
Values are presented as mean±standard deviation or number of cases (%).
QCT: quantitative computed tomography, DXA: dual-energy X-ray absorptiometry, BMD: bone mineral density.
Table 2. BMD evaluation and osteoporosis medication prescription in the QCT and DXA groups
Variable
Group
P-value
QCT (n=47) DXA (n=51)
Discharge
BMD evaluation 47 (100.0) 20 (39.2) <0.001
Prescription 33 (70.2)0 15 (29.4) <0.001
PO 2 wk
BMD evaluation 0 (0.0)0 00 (0.00) -
Prescription 1 (2.1)0 1 (2.0) >0.999
PO 6 wk
BMD evaluation 0 (0.0)0 4 (7.8) 0.0.118
Prescription 2 (4.3)0 3 (5.9) >0.999
PO 12 wk
BMD evaluation 0 (0.0)0 12 (23.5) 0.0.004
Prescription 5 (10.6) 12 (23.5) 0.0.113
Total (cumulative)
BMD evaluation 47 (100.0) 36 (70.6) <0.001
Prescription 41 (87.2)0 31 (60.8) 0.0.003
Values are presented as number of cases (%).
BMD: bone mineral density, PO: postoperative.
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CT. The osteoporosis evaluation rate by DXA increased
from 39.2% at discharge to 70.6% at PO week 12 after
surgery (Fig. 2). The difference between the cumulative
evaluation rates at the final follow-up at PO week 12 was
Fig. 2. Cumulative bone mineral density (QCT) evaluation rate (%) according to time point and group (QCT vs. DXA). All of the
patients in the QCT group were evaluated for osteoporosis because simultaneous CT and QCT were performed at the first
visit to emergency department.
QCT: quantitative computed tomography, DXA: dual-energy X-ray absorptiometry, PO: postoperative.
Fig. 3. Cumulative prescription rate (%) according to time and group (QCT vs. DXA).
* Significant difference in the rate of new osteoporosis medication prescriptions at individual time points between the two groups.
A significant difference in prescription rate was found at discharge (P<0.001), whereas no difference was found thereafter.
� Significant difference in cumulative prescription rate of osteoporosis medication at postoperative (PO) week 12 was observed
between the two groups.
QCT: quantitative computed tomography, DXA: dual-energy X-ray absorptiometry, BMD: bone mineral density.
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significant (100% vs. 70.6%, P<0.001; Fig. 2). The difference
between the rates of osteoporosis medication prescription
at discharge was also significant (70.2% in the QCT
group vs. 29.4% in the DXA group, P<0.001), whereas no
significant difference was observed at later time points
(Fig. 3). A significant difference in cumulative prescription
rate at PO week 12 was observed (87.2% in the QCT
group vs. 60.8% in the DXA group, P=0.003; Fig. 3).
DISCUSSION
The present study evaluated the efficacy of simultaneous
CT and QCT in patients with OHF by analyzing the
prescription rate of osteoporosis medications in comparison
with that of the conventional DXA. The results demonstrate
that simultaneous CT and QCT resulted in a better prescription
rate of osteoporosis medications, consistent with our
hypothesis.
We should note the limitations of this study. First, although
prospectively conducted, this is not a randomized controlled
study. We assigned patients to the QCT group when
simultaneous performance of QCT and hip CT was possible;
otherwise, the patients were assigned to the DXA group.
Thus, we assigned the patients according to the possibility
of examination before surgery. This non-random assignment
may have introduced a bias, even though no significant
difference in demographic characteristics was observed
between the two consecutive patient groups. To minimize
the influence of prescription, the residents who prescribed
osteoporosis medication before discharge were blinded to
the purpose or concept of the study. However, they were
hardly blinded to the method of the study because osteoporosis
evaluation was performed during the study period. For this
reason, the prescription rates of osteoporosis medication
in our study might have been much higher in both groups
than other studies20,21). However, we believe that if the new
evaluation method can increase the prescription rate of anti-
osteoporosis medication, it would be useful for patients.
Second, the radiation dose is well known to be higher in
QCT (0.060-3.000μSv) than in DXA (0.009-0.013μSv)22-25).
However, the radiation dose in QCT is still within the
acceptable range, and performing osteoporosis evaluation
is very convenient for patients. Thus, surgeons may consider
our new method depending on the situation. The evaluation
time was 15.2±2.3 minutes for QCT, whereas for DXA
it took an additional 40.0±2.3 minutes to transfer patients
from the admission room to the DXA evaluation room and
back to the admission room (data not shown). Furthermore,
even though DXA evaluation was performed after surgery,
the patients complained of severe pain throughout the entire
DXA evaluation. Again, surgeons may consider simultaneous
QCT and hip CT scans, considering the convenience of
evaluation and higher prescription rate of osteoporosis
medication. Although the cost may differ among countries,
but a QCT test is about 20% cheaper than the BMD test
using conventional DXA in our country, indicating that
our new method is also less costly.
Patients with OHF have quite high mean mortality rate
(15-25% within 1 year of injury) due to accompanying
complications and other causes3,7,26-28). Moreover, OHFs
have a negative impact on patient quality of life over a long
period29). According to a study by Boonen et al.30), post-
injury quality of life deteriorates in comparison with pre-
injury quality of life, despite functional recovery. Effective
management after OHF treatment is well known to be
important for lowering the risk of associated fractures,
mortality, and morbidity2-4). However, it is quite surprising
that the rates of evaluation (<15% of the patients11)) and
osteoporosis medication prescription (<25% of the
patients9,10,12,13)) by physicians after OHF are quite low.
Surgeons need to care more about osteoporosis treatment
after OHF because they are responsible for preventing
associated fractures and reducing mortality and morbidity
rates. We designed this study because osteoporosis evaluation
is often omitted since patients feel severe pain even after
surgery. When patients visit the outpatient clinic later,
orthopedic surgeons often seem to neglect to evaluate them
for osteoporosis because they tend to focus on the treatment
of the fracture itself. We believe that evaluating osteoporosis
simultaneously with routine OHF evaluation on hip CT
would be helpful for prescribing osteoporosis medication
after surgery. As we hypothesized, physician prescription
rate significantly improved until PO month 3 when QCT
was performed simultaneously with hip CT. We hope
that our new method would help surgeons improve the
management of osteoporosis and also be convenient for
patients.
Some studies have suggested that bisphosphonate appears
to delay fracture healing31,32), whereas other studies reported
that early initiation of bisphosphonate does not affect healing
or clinical outcomes of osteoporotic fractures33,34). Despite
this controversy, we prescribed bisphosphonate after fracture
surgery, because we thought that minimizing the number of
patients with missed opportunity of osteoporosis treatment
after hip surgery would be more beneficial than the potential
negative effect of bisphosphonate on fracture healing.
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CONCLUSION
Our new method of simultaneous CT and QCT significantly
increased the osteoporosis evaluation and prescription rates
in patients with OHF. The use of this method may enable
appropriate and consistent prescription of osteoporosis
medications, eventually leading to patient medication
compliance. Moreover, we expect this simultaneous scanning
to contribute to the reduction of subsequent fractures,
mortality, and morbidity through PO care for osteoporosis
in patients with OHF.
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